Eid 1996.

Methods	Study design: parallel group Duration of study: not reported Duration of follow‐up: 36 months
Participants	Country: Italy Setting: single centre Inclusion criteria: postmenopausal kidney transplant recipients Number: treatment group (29); control group (29) Age range (years): treatment group (47 to 57); control group (48 to 58) Sex (M/F): treatment group (0/29); control group (0/29) Exclusion criteria: not reported
Interventions	Treatment group Uninterrupted percutaneous 17 β‐estradiol: 50 µg Medroxyprogesterone: 10 mg/d on days 16 to 28 of cycle Control group 1,25 dihydroxyvitamin D3 (oral): 0.25 µg/d
Outcomes	BMD at lumbar spine by DEXA
Notes	Abstract‐publication only Funding source: not reported Trial registration: not applicable as published before end of 2005
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Treatments were sufficiently different that blinding was unlikely
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	High risk	21/58 participants did not complete follow‐up
Selective reporting (reporting bias)	High risk	Patient‐centred outcomes not captured or reported systematically
Other bias	Unclear risk	Insufficient data to perform adjudication